Melanie J. Davies

Apr 2, 2024 | jacc.org | Mark C. Petrie |Barry A. Borlaug |Javed Butler |Melanie J. Davies

Introduction In the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program, the glucagon-like peptide-1 receptor agonist (GLP-1RA) semaglutide, at a weight-management dose of 2.4 mg once weekly, reduced heart failure (HF)–related symptoms, physical limitations, and body weight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).1,2 Semaglutide also improved exercise function and lowered levels of systemic inflammation with a...

Mar 12, 2024 | drc.bmj.com | Laura Heathcote |Daniel Pollard |Alan Brennan |Melanie J. Davies

WHAT IS ALREADY KNOWN ON THIS TOPICHOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICYIntroductionIt is estimated that diabetes affects just under half a billion people worldwide, of whom approximately 90% in high-income countries have type 2 diabetes (T2D).1 People with T2D have an elevated risk of developing serious complications such as renal failure, blindness, amputation, cardiovascular disease (CVD), depression, and osteoarthritis.

Mar 1, 2024 | drc.bmj.com | Laura Heathcote |Daniel Pollard |Alan Brennan |Melanie J. Davies

MethodsThis analysis was a lifetime horizon, model-based cost-utility analysis using the School for Public Health Research (SPHR) Diabetes Prevention Model v3.2 (hereafter referred to as “the model”),19 20 as prespecified in the PROPELS health economics analysis plan. A model-based analysis was conducted for two reasons.

Oct 8, 2023 | jacc.org | Javed Butler |Steen Z. Abildstrøm |Barry A. Borlaug |Melanie J. Davies

Introduction Patients with heart failure (HF) have been traditionally classified based on left ventricular ejection fraction (LVEF) into those with HF and reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).1 Clinical trials have used this classification to determine eligibility; however, the criteria demarcating the 2 groups have ranged between >40%, >45%, or ≥50% for HFpEF and ≤40 or ≤35% for HFrEF, resulting in variations in definitions as well as an evidence...

Aug 28, 2023 | cell.com | Barry A. Borlaug |Baylor Scott |Melanie J. Davies |Mark C. Petrie

In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF. Main textThe burgeoning prevalence of heart failure with preserved ejection fraction (HFpEF) is well recognized.